Menarini secures European rights to obesity drug from Gan & Lee
Menarini Group, an Italian pharmaceutical firm, has obtained European commercialization rights to a GLP-1 agonist developed by China's Gan & Lee. This deal allows Menarini to enter the obesity treatment market and compete with existing GLP-1 therapies in Europe.
Expanded Detail
EXPANDED:
Menarini, an Italian pharmaceutical company, has secured the rights to market a GLP-1 agonist in Europe. The drug originates from Gan & Lee, a
Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
Related stories
NeuShen secures $80M to advance three clinical-stage brain therapies · Drug development
GSK secures global rights to Hutchmed's dual-target cancer therapy in $110M upfront deal · Cancer research
Haisco licenses inflammatory disease drug to Sentivera; ViiV's HIV drug cleared for newborns · Drug development
Roche pays $190M upfront for Hanmi's muscle-sparing obesity drug · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Italy's Menarini gets into obesity with European rights to GLP-1 from China's Gan & Lee.” Browse more stories.